ClinicaliQ Trial Snapshot
- Cerebellar Mutism Syndrome Study — Recruiting • Oncology • NCT02300766.
- What is being tested: The study investigates the mechanisms underlying Cerebellar Mutism Syndrome (CMS), a postoperative complication affecting up to 25% of children undergoing posterior fossa tumor surgery, and explores potential clinical interventions to prevent or mitigate this condition.
- Patient eligibility overview: The trial enrolls pediatric patients undergoing surgical treatment for posterior fossa tumors, focusing on those at risk of developing CMS and potentially comparing outcomes between different surgical or perioperative management approaches.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to determine why up to 25% of the pediatric patients who have surgery for a tumor in the posterior fossa develops the Cerebellar Mutism Syndrome (CMS). Furthermore the purpose is to explore the clinical course and the best treatment of the syndrome.
Eligibility Snapshot
- : * Age < 18 years at the date of first imaging showing this tumour * Tumour in the cerebellum/4th ventricle/brainstem with intention to treat with surgical resection or open biopsy. Second and further surgeries are also included. * Informed consent from custodial parent(s)
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.